PENpics Studio / Shutterstock.com
In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
In the third article of a four-part series on experimental use exemptions from infringement in the UK, we consider the expansion of the original experimental use exemption (Section 60(5)(b) UK Patents Act [UKPA] 1977) introduced by the Legislative Reform (Patents) Order 2014/1997.
Expanded experimental use exemption
Sections 60(6D)-(6G) UKPA 1977 were added to the UKPA in order to expand upon the original exemption provided by Section 60(5)(b) to broadly cover acts undertaken for the purpose of a “medicinal product assessment”. The new provisions came into force in October 2014.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Marks & Clerk, generics, biosimilars, infringement, patents, application, EU directive, human trials